JP2020504120A - インテグリンアンタゴニスト - Google Patents

インテグリンアンタゴニスト Download PDF

Info

Publication number
JP2020504120A
JP2020504120A JP2019534956A JP2019534956A JP2020504120A JP 2020504120 A JP2020504120 A JP 2020504120A JP 2019534956 A JP2019534956 A JP 2019534956A JP 2019534956 A JP2019534956 A JP 2019534956A JP 2020504120 A JP2020504120 A JP 2020504120A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
compound
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019534956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504120A5 (enExample
Inventor
ピーター ジー． ルミンスキ，
ピーター ジー． ルミンスキ，
デイビッド ダブリュー． グリッグス，
デイビッド ダブリュー． グリッグス，
スコット シーワート，
スコット シーワート，
Original Assignee
セントルイス ユニバーシティ
セントルイス ユニバーシティ
インダロ セラピューティクス， インコーポレイテッド
インダロ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントルイス ユニバーシティ, セントルイス ユニバーシティ, インダロ セラピューティクス， インコーポレイテッド, インダロ セラピューティクス， インコーポレイテッド filed Critical セントルイス ユニバーシティ
Publication of JP2020504120A publication Critical patent/JP2020504120A/ja
Publication of JP2020504120A5 publication Critical patent/JP2020504120A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2019534956A 2016-12-29 2017-12-28 インテグリンアンタゴニスト Pending JP2020504120A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US62/440,253 2016-12-29
US201762471882P 2017-03-15 2017-03-15
US62/471,882 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (2)

Publication Number Publication Date
JP2020504120A true JP2020504120A (ja) 2020-02-06
JP2020504120A5 JP2020504120A5 (enExample) 2021-01-21

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534956A Pending JP2020504120A (ja) 2016-12-29 2017-12-28 インテグリンアンタゴニスト

Country Status (14)

Country Link
US (1) US11306084B2 (enExample)
EP (1) EP3562826A4 (enExample)
JP (1) JP2020504120A (enExample)
KR (1) KR20190100232A (enExample)
CN (1) CN110177787A (enExample)
AU (1) AU2017393297A1 (enExample)
BR (1) BR112019012515A2 (enExample)
CA (1) CA3045491A1 (enExample)
CO (1) CO2019007023A2 (enExample)
IL (1) IL267686A (enExample)
MX (1) MX2019007797A (enExample)
PH (1) PH12019501514A1 (enExample)
RU (1) RU2019116820A (enExample)
WO (1) WO2018132268A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
US20240245682A1 (en) * 2022-12-27 2024-07-25 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
JP2006513218A (ja) * 2002-12-20 2006-04-20 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物
JP2006518333A (ja) * 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US20140051715A1 (en) * 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
JP2015524412A (ja) * 2012-07-18 2015-08-24 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572690A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA3042707A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as .alpha.v integrin inhibitors
KR102506327B1 (ko) 2016-11-08 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 αV 인테그린 길항제로서의 인다졸 유도체
JP7128811B2 (ja) 2016-11-08 2022-08-31 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン
LT3538528T (lt) 2016-11-08 2021-03-10 Bristol-Myers Squibb Company Pirolo amidai, kaip alfa v integrino inhibitoriai
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
JP2006513218A (ja) * 2002-12-20 2006-04-20 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物
JP2006518333A (ja) * 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US20140051715A1 (en) * 2012-07-18 2014-02-20 Saint Louis University 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists
JP2015524412A (ja) * 2012-07-18 2015-08-24 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PENNING, THOMAS D. ET AL.: "Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 12, JPN6021044729, 2006, pages 3156 - 3161, ISSN: 0004790851 *

Also Published As

Publication number Publication date
CA3045491A1 (en) 2018-07-19
BR112019012515A2 (pt) 2019-11-19
CO2019007023A2 (es) 2019-07-31
EP3562826A1 (en) 2019-11-06
PH12019501514A1 (en) 2020-09-14
IL267686A (en) 2019-08-29
US20190345155A1 (en) 2019-11-14
EP3562826A4 (en) 2020-08-26
WO2018132268A8 (en) 2019-06-20
KR20190100232A (ko) 2019-08-28
MX2019007797A (es) 2019-10-21
WO2018132268A1 (en) 2018-07-19
RU2019116820A (ru) 2021-01-29
US11306084B2 (en) 2022-04-19
CN110177787A (zh) 2019-08-27
AU2017393297A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
CN104640857B (zh) 作为整合素拮抗剂的β氨基酸衍生物
JP5564251B2 (ja) キナーゼカスケードを調節するためのビアリール組成物および方法
RU2729518C2 (ru) Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
JP2020504120A (ja) インテグリンアンタゴニスト
US8901297B2 (en) Compositions for modulating a kinase cascade and methods of use thereof
WO2011118672A1 (ja) 血漿カリクレイン阻害剤
JP5309033B2 (ja) ヘテロアリールシクロプロパンカルボキサミド及び薬剤としてのその使用
CN103097340A (zh) 治疗活性组合物及其使用方法
JP2009542680A5 (enExample)
WO2020009889A1 (en) ALPHAvBETA1 INTEGRIN ANTAGONISTS
JP4274522B2 (ja) Ｘａ因子阻害剤としてのグアニジンおよびアミジン誘導体
CN101213184A (zh) 包含不饱和或环状连接基团的杂芳基取代的酰胺及其作为药物的用途
JP5781093B2 (ja) 新たな置換イソキノリン誘導体
JPH06509318A (ja) トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物
HK1209749B (en) Beta amino acid derivatives as integrin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220606